Cantor Fitzgerald Reiterates Sell on bluebird bio (BLUE) Following ASH Abstracts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
BTIG Defends bluebird bio (BLUE) Amid ASH Abstracts Sell-Off
November 3, 2016 12:44 PM EDTBTIG is out in defense of bluebird bio (Nasdaq: BLUE) following release of ASH abstracts earlier this morning. The firm rates bluebird at Buy with a price target of $83.
The firm commented, BLUE has experienced a significant sell-off as a result of weak... More
bluebird bio (BLUE) ASH Abstract Data Fairly Consistent With Previously Published Data - Leerink
November 3, 2016 11:58 AM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and $80 price target on bluebird bio (NASDAQ: BLUE) saying the ASH abstract data was fairly consistent with previously published data.
Schmidt commented, " This morning, abstracts for the upcoming American Society of Hematology (ASH) Annual Meeting were... More
bluebird bio (BLUE) to Present New Data from Three LentiGlobin Studies at ASH
November 3, 2016 9:04 AM EDTbluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that data from its ongoing clinical studies of LentiGlobin drug product in transfusion-dependent -thalassemia (TDT) and severe sickle cell disease (SCD) will be highlighted in oral and poster presentations... More
